Pancreatic Ductal Adenocarcinoma: The Dawn of the Era of Nuclear Medicine?

Pancreatic ductal adenocarcinoma (PDAC), accounting for 90–95% of all pancreatic tumors, is a highly devastating disease associated with poor prognosis. The lack of accurate diagnostic tests and failure of conventional therapies contribute to this pejorative issue. Over the last decade, the advent o...

Descripción completa

Detalles Bibliográficos
Autores principales: Montemagno, Christopher, Cassim, Shamir, De Leiris, Nicolas, Durivault, Jérôme, Faraggi, Marc, Pagès, Gilles
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232627/
https://www.ncbi.nlm.nih.gov/pubmed/34203923
http://dx.doi.org/10.3390/ijms22126413

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8232627/
https://www.ncbi.nlm.nih.gov/pubmed/34203923
http://dx.doi.org/10.3390/ijms22126413

Ejemplares similares